AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

10.530

+0.3603.54%

Volume:672.72K

Turnover:6.97M

Market Cap:1.33B

PE:9.70

High:10.530

Open:10.110

Low:10.110

Close:10.170

Loading ...

Overview Company News Filings

NewMarket Unit to Increase Ammonium Perchlorate Production Capacity

MT Newswires Live

Here are the top 10 ASX 200 shares today

Australian Shares Rise Amidst Temporary Reprieve for Electronic Tariffs; EBR Systems Receives US FDA Approval for Heart Failure Treatment Device

MT Newswires Live

BUZZ-Australian healthcare stocks rise as Bell Potter sees most cos unfazed by potential tariffs

FDA OK for Neuren’s first ever Phase 3 trial in children with Phelan-McDermid syndrome

The Market Herald

Monday’s HotCopper Trends: Invictus exploration, Neuren’s FDA tick | April 14, 2025

The Market Herald

Why DroneShield, Fiducian, Neuren, and Newmont shares are storming higher

BUZZ-Australia's Neuren Pharmaceuticals rises on FDA trial update

Neuren Pharmaceuticals Confirms Primary Endpoints for Phase Three Phelan-McDermid Syndrome Drug Candidate Trial

MT Newswires Live

Investors Don't See Light At End Of Neuren Pharmaceuticals Limited's (ASX:NEU) Tunnel

Simply Wall St.

ASX Market Close: Reject Shop rockets ~ 110% after Canadian offer | March 27, 2025

The Market Herald

Neuren Pharmaceuticals Starts Development of Potential Treatment for Infant Brain Injury; Shares Up 3%

MT Newswires Live

Neuren Investors Get Free Exposure to Second Drug Candidate -- Market Talk

Neuren Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

News Flash: 6 Analysts Think Neuren Pharmaceuticals Limited (ASX:NEU) Earnings Are Under Threat

Simply Wall St.

Neuren Pharmaceuticals Receives First Milestone Payment for Rett Syndrome Drug; Shares Down 6%

MT Newswires Live

BRIEF-Neuren Pharmaceuticals Receives First Daybue Sales Milestone Payment

Neuren Pharmaceuticals Ltd - Neuren Receives First Daybue Sales Milestone Payment of US$50 Mln

THOMSON REUTERS

Neuren Pharmaceuticals Posts Lower 2024 Earnings as Revenue Drops

MT Newswires Live

Neuren Pharmaceuticals Posts 2024 EPS of AU$1.0861, Revenue of AU$227.8 Million

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NEU.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":10.53,"timestamp":1744870320000,"preClose":10.17,"halted":0,"volume":672718,"delay":0,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":109796852,"shares":126063594,"eps":1.086099,"marketStatus":"Not Yet Opened","change":0.36,"latestTime":"04-17 16:12:00 AEST","open":10.11,"high":10.53,"low":10.11,"amount":6973295,"amplitude":0.041298,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.086099,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":10.17,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.5667919524504145,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":109796852,"roa":"34.05%","roe":"49.92%","lyrEps":1.111713,"volumeRatio":0.5667919524504145,"shares":126063594,"dividePrice":0,"high":10.53,"amplitude":0.041298,"preClose":10.17,"low":10.11,"week52Low":8.61,"pbRate":"3.65","psRate":"6.12","week52High":24,"institutionHeld":0,"latestPrice":10.53,"eps":1.086099,"divideRate":0,"volume":672718,"delay":0,"ttmEps":1.086099,"open":10.11,"prevYearClose":12.5,"prevWeekClose":10.53,"prevMonthClose":11.93,"prevQuarterClose":11.93,"fiveDayClose":9.57,"twentyDayClose":12.6,"sixtyDayClose":14.01},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529806558","title":"NewMarket Unit to Increase Ammonium Perchlorate Production Capacity","url":"https://stock-news.laohu8.com/highlight/detail?id=2529806558","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529806558?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:41","pubTimestamp":1745239295,"startTime":"0","endTime":"0","summary":"NewMarket  unit American Pacific said Monday its board approved up to $100 million in capital investment to expand its ammonium perchlorate production capabilities to keep pace with solid rocket motor demand.American Pacific said the expected investment will allow it to build an additional production line, increasing capacity by over 50%, which in turn will enable American Pacific to meet the demand of the US military and space launch programs.American Pacific said the project requires the NewMarket board's approval and is currently anticipated to be completed next year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK4109","BK7508","NEU.AU","NEU"],"gpt_icon":0},{"id":"2527186297","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2527186297","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527186297?lang=en_us&edition=fundamental","pubTime":"2025-04-14 15:01","pubTimestamp":1744614107,"startTime":"0","endTime":"0","summary":"It was a flying start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. After a rough end to last week, investors came back from the weekend with a spring in their steps. By the ti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/here-are-the-top-10-asx-200-shares-today-14-april-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SMR.AU","BK7067","XJO.AU","BK7504","PME.AU","NEU.AU","PNV.AU","BK7501","BK7129","BK7016","WHC.AU","BK7507","CU6.AU","SDR.AU","BK7083","MSB.AU","BK7096","BK7126","BK7094","BK7062","PNI.AU","BK7095","BK7508","MIN.AU"],"gpt_icon":0},{"id":"2527977273","title":"Australian Shares Rise Amidst Temporary Reprieve for Electronic Tariffs; EBR Systems Receives US FDA Approval for Heart Failure Treatment Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2527977273","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527977273?lang=en_us&edition=fundamental","pubTime":"2025-04-14 14:59","pubTimestamp":1744613994,"startTime":"0","endTime":"0","summary":"Australian shares rose on Monday after US President Trump temporarily exempted China from a 125% tariff on popular electronics and introduced flat 10% tariffs on electronics around the globe.The S&P/A","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK4081","EBR","BK7007","IE00B1B80R65.USD","COL.AU","XJO.AU","BK7040","WOW.AU","NEU.AU","BK7501","BK7511","BK7096","BK7082","XAO.AU","CRT","XKO.AU","EBR.AU","BK4213"],"gpt_icon":0},{"id":"2527978495","title":"BUZZ-Australian healthcare stocks rise as Bell Potter sees most cos unfazed by potential tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2527978495","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527978495?lang=en_us&edition=fundamental","pubTime":"2025-04-14 13:17","pubTimestamp":1744607871,"startTime":"0","endTime":"0","summary":"BUZZ-Australian healthcare stocks rise as Bell Potter sees most cos unfazed by potential tariffs** Index of Australian Healthcare stocks .AXHJ rises 1.9%, tracking broadly positive market sentiment .A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nL4N3QS0C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAN.AU","BK7048","BK7126","CSL.AU","PNV.AU","BK7511","BK7508","BK7501","TRJ.AU","NEU.AU","ARX.AU","BK7503","BK7067","BK7096"],"gpt_icon":0},{"id":"2527268739","title":"FDA OK for Neuren’s first ever Phase 3 trial in children with Phelan-McDermid syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2527268739","media":"The Market Herald","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527268739?lang=en_us&edition=fundamental","pubTime":"2025-04-14 10:11","pubTimestamp":1744596660,"startTime":"0","endTime":"0","summary":"Neuren Pharma  has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome  – the first ever to be conducted.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.A rare disorder, PMS ultimately leads to developmental disabilities in children with the condition that acts on chromosomes. The condition can be inherited genetically, but it can also form sporadically on its own.The FDA approval for Neuren’s Phase 3 trial comes on the back of a meeting it held with regulators in the U.S. establishing primary endpoints for the study.In other words: Deciding what milestones the company would put in place to determine whether or not its drug NNZ-2591 is effective in treating PMS. . The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and cons","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/fda-ok-for-neurens-first-ever-phase-3-trial-in-children-with-phelan-mcdermid-syndrome-2025-04-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2527994124","title":"Monday’s HotCopper Trends: Invictus exploration, Neuren’s FDA tick | April 14, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527994124","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527994124?lang=en_us&edition=fundamental","pubTime":"2025-04-14 10:08","pubTimestamp":1744596480,"startTime":"0","endTime":"0","summary":"The ASX has been up 1% higher at 7,721 points.Invictus Energy  has been among the most watched on HotCopper forums after the company confirmed Musuma-1 as the first high-impact exploration well to be drilled outside the Mukuyu gas-condensate discovery area, targeting a new play type in the Cabora Bassa Basin.Neuren Pharmaceuticals  has also been trending on news the primary endpoints for its Phase 3 pivotal clinical trial of its drug in Phelan-McDermid syndrome have been confirmed in a meeting with the U.S. FDA.And, finally, Bellevue Gold  has revised its full-year production guidance down and scrapped itsfive-year growth planafter “uncharacteristic geological factors” hindered the gold miner’s output in the March quarter.Bellevue Gold was $1.145 before its trading suspension.Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.The material provided in this article is for information onl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/mondays-hotcopper-trends-invictus-exploration-neurens-fda-tick-april-14-2025-2025-04-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["IVZ.AU","BK7096","BK7104","NEU.AU","BK7142","BGL.AU","BK7508"],"gpt_icon":0},{"id":"2527928510","title":"Why DroneShield, Fiducian, Neuren, and Newmont shares are storming higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2527928510","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527928510?lang=en_us&edition=fundamental","pubTime":"2025-04-14 10:00","pubTimestamp":1744596055,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) has followed Wall Street's lead and is pushing higher. At the time of writing, the benchmark index is up 1.1% to 7,728.6 points. Four ASX shares that are rising more th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/why-droneshield-fiducian-neuren-and-newmont-shares-are-storming-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7104","BK7062","NEU.AU","NEM.AU","DRO.AU","BK7115","XJO.AU","BK7096","BK7508","FID.AU"],"gpt_icon":0},{"id":"2527917449","title":"BUZZ-Australia's Neuren Pharmaceuticals rises on FDA trial update","url":"https://stock-news.laohu8.com/highlight/detail?id=2527917449","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527917449?lang=en_us&edition=fundamental","pubTime":"2025-04-14 09:01","pubTimestamp":1744592476,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharmaceuticals rises on FDA trial update** Shares of Neuren Pharmaceuticals NEU.AX up 16% at A$10.7, their biggest intraday percentage gain since December 18, 2023** Stock is top gainer in the ASX 200 benchmark index .AXJO, which is up 0.6% ** The drugmaker says primary endpoints for its Phase 3 trial of NNZ-2591 in Phelan-McDermid syndrome , a genetic disorder, confirmed at a meeting with the U.S. Food and Drug Administration** Stock down 26.5% this year, as of last close  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nL4N3QS02C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2527912381","title":"Neuren Pharmaceuticals Confirms Primary Endpoints for Phase Three Phelan-McDermid Syndrome Drug Candidate Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2527912381","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527912381?lang=en_us&edition=fundamental","pubTime":"2025-04-14 08:40","pubTimestamp":1744591233,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  reported that primary endpoints for its planned single phase-three clinical trial of its drug candidate NNZ-2591 as a treatment for Phelan-McDermid syndrome were confirmed at a meeting with the US Food and Drug Administration, according to a Monday Australian bourse filing.The co-primary endpoints in the double-blind placebo-controlled study of treatment for 13 weeks will be the change from baseline in the receptive communication sub-domain of the Vineland adaptivebehavior scales, third edition, and the overall score in the Phelan-McDermid syndrome assessment of change.The firm said it remains on track to commence the phase three trial by the middle of the year, subject to regulatory review of the final version of the trial protocol.Both measures included in the primary endpoints showed clinically meaningful improvement in the firm's phase two open-label clinical trial, the filing noted.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2524487570","title":"Investors Don't See Light At End Of Neuren Pharmaceuticals Limited's (ASX:NEU) Tunnel","url":"https://stock-news.laohu8.com/highlight/detail?id=2524487570","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524487570?lang=en_us&edition=fundamental","pubTime":"2025-04-02 05:51","pubTimestamp":1743544267,"startTime":"0","endTime":"0","summary":"With a price-to-earnings (or \"P/E\") ratio of 10.1x Neuren Pharmaceuticals Limited ( ASX:NEU ) may be sending bullish...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/investors-dont-see-light-at-end-of-neuren-pharmaceuticals-li","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK4109","BK7508","NEU.AU","ISBC","NEU","BK7096"],"gpt_icon":0},{"id":"2522319667","title":"ASX Market Close: Reject Shop rockets ~ 110% after Canadian offer | March 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522319667","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522319667?lang=en_us&edition=fundamental","pubTime":"2025-03-27 13:54","pubTimestamp":1743054840,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.38% at 7,969 points.Energy was the best performing sector, up1%, followed by Staples, up 0.4%, and Materials, up 0.33%.Real Estate was the biggest loser, down 2.2%, followed, IT, down 2%, and Discretionary, down 1%.Core Lithium  closed up 5.2% following the release of anupdateon its Finniss Lithium Operation.Neuren Pharmaceuticals  finished up 0.67% on news the company is developing a new product to treat infant injuries when a baby’s brain does not receive enough oxygen or blood flow before or shortly after birth.And, Reject Shop  has closed up 109% after investors flocked to the stock as the company received a takeover offer. Canada’s Dollarama  cut a deal to buy Reject Shop for $259 million.Domain  closed down 4.9% after CoStar Group  improved its takeover offer, from $4.20 cash per share to $4.43 per share.And, WiseTech  closed down 2% as investors reacted to Australian Super selling its entire $580M stake in the company. AusSuper’s move came due to “govern","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-reject-shop-rockets-110-after-canadian-offer-march-27-2025-2025-03-27/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7095","PME.AU","LU2210150020.SGD","BK4585","BK7503","BK4123","IE0009356076.USD","BK4548","BK7002","BK7016","BK7096","BK7508","BK7504","CSGP","DHG.AU","LU0708995401.HKD","BK7153","LU0390134368.USD","IE0004445239.USD","LU0672654240.SGD","TRS.AU","LU0320765059.SGD","WTC.AU","NEU.AU","LU2210149790.SGD","BK4079","BK7094","BK7041","BK4588","LU2095319765.USD","LU0109391861.USD","CXO.AU","LU1267930730.SGD"],"gpt_icon":0},{"id":"2522365634","title":"Neuren Pharmaceuticals Starts Development of Potential Treatment for Infant Brain Injury; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522365634","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522365634?lang=en_us&edition=fundamental","pubTime":"2025-03-27 08:21","pubTimestamp":1743034899,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  started the development of NNZ-2591 for the potential treatment of hypoxic-ischemic encephalopathy , according to a Thursday filing with the Australian bourse.HIE is a type of brain injury resulting from inadequate oxygen or blood flow in a baby's brain before or shortly after birth, the filing said.The company aims for a pre-investigational new drug meeting with the US Food and Drug Administration in the fourth quarter of the year before initiating a clinical trial in patients with HIE, per the filing.Shares were up 3% in morning trade Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","HIE","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2518090297","title":"Neuren Investors Get Free Exposure to Second Drug Candidate -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2518090297","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518090297?lang=en_us&edition=fundamental","pubTime":"2025-03-12 07:33","pubTimestamp":1741735980,"startTime":"0","endTime":"0","summary":"2333 GMT - Licensing income from the Daybue treatment for Rett Syndrome alone supports Neuren Pharmaceuticals's share price, meaning investors effectively get exposure to its next drug candidate \"for free,\" Bell Potter says. Neuren is upbeat about the potential of NNZ-2591 as a treatment of several neurodevelopmental disorders. It has cited positive results from Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Still, Bell Potter says it will be two years until Neuren's next major clinical catalyst: the first Phase 3 trial results for NNZ-2591. \"Neuren has unrivalled balance sheet strength to prosecute future NNZ-2591 development yet effectively zero value is currently attributed to this asset, likely due to the Phase 3 readout timing,\" analyst Thomas Wakim says. Bell Potter retains a \"buy\" call on Neuren. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK7096","NEU.AU","ISBC","BK7508"],"gpt_icon":0},{"id":"2517198674","title":"Neuren Pharmaceuticals Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2517198674","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517198674?lang=en_us&edition=fundamental","pubTime":"2025-03-05 04:52","pubTimestamp":1741121564,"startTime":"0","endTime":"0","summary":"ASX:NEU Revenue and Expenses Breakdown March 4th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 13%. Earnings per share  also surpassed analyst estimates by 21%.In the last 12 months, the only revenue segment was Commercial Products contributing AU$213.2m. The most substantial expense, totaling AU$37.1m were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how NEU's revenue and expenses shape its earnings.Looking ahead, revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Australia are expected to grow by 44%.The company's shares are down 7.9% from a week ago.It is worth noting though that we have found 1 warning sign for Neuren Pharmaceuticals that you need to take into consideration.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuren-pharmaceuticals-full-2024-earnings-205244548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NEU.AU"],"gpt_icon":0},{"id":"2516158562","title":"News Flash: 6 Analysts Think Neuren Pharmaceuticals Limited (ASX:NEU) Earnings Are Under Threat","url":"https://stock-news.laohu8.com/highlight/detail?id=2516158562","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516158562?lang=en_us&edition=fundamental","pubTime":"2025-03-02 06:42","pubTimestamp":1740868953,"startTime":"0","endTime":"0","summary":"The analysts covering Neuren Pharmaceuticals Limited  delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Both revenue and earnings per share  forecasts went under the knife, suggesting analysts have soured majorly on the business.Following the latest downgrade, the current consensus, from the six analysts covering Neuren Pharmaceuticals, is for revenues of AU$66m in 2025, which would reflect a stressful 66% reduction in Neuren Pharmaceuticals' sales over the past 12 months. Statutory earnings per share are anticipated to dive 72% to AU$0.26 in the same period. Prior to this update, the analysts had been forecasting revenues of AU$122m and earnings per share  of AU$0.35 in 2025. It looks like analyst sentiment has declined substantially, with a sizeable cut to revenue estimates and a pretty serious decline to earnings per share numbers as well.ASX:NEU Earnings and Revenue Growth March 1st 2025. Of course, se","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/news-flash-6-analysts-think-224233508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NEU","NEU.AU"],"gpt_icon":0},{"id":"2514024361","title":"Neuren Pharmaceuticals Receives First Milestone Payment for Rett Syndrome Drug; Shares Down 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514024361","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514024361?lang=en_us&edition=fundamental","pubTime":"2025-02-28 10:17","pubTimestamp":1740709061,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  received its first sales milestone payment of $50 million for the first year that the net sales of Rett syndrome drug Daybue exceeded $250 million in North America, according to a Friday filing with the Australian bourse.The company's Nasdaq-listed partner Acadia Pharmaceuticals reported $348.4 million net sales of the drug in the US in 2024, the filing said.The company will receive the second milestone payment from commercialization of the drug when net sales exceed $500 million, according to the filing.Neuren Pharmaceuticals shares fell 6% in afternoon trade Friday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2514365891","title":"BRIEF-Neuren Pharmaceuticals Receives First Daybue Sales Milestone Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2514365891","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514365891?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:23","pubTimestamp":1740705806,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Receives First Daybue Sales Milestone Payment Feb 28 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:NEUREN RECEIVES FIRST DAYBUE SALES MILESTONE PAYMENT OF US$50 MILLIONFurther company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU"],"gpt_icon":0},{"id":"2514631368","title":"Neuren Pharmaceuticals Ltd - Neuren Receives First Daybue Sales Milestone Payment of US$50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514631368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514631368?lang=en_us&edition=fundamental","pubTime":"2025-02-28 08:46","pubTimestamp":1740703560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2514351570","title":"Neuren Pharmaceuticals Posts Lower 2024 Earnings as Revenue Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2514351570","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514351570?lang=en_us&edition=fundamental","pubTime":"2025-02-28 06:51","pubTimestamp":1740696690,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  reported Friday 2024 earnings of AU$1.0861 per diluted share, down from AU$1.2012 a year earlier.Analysts polled by Visible Alpha expected a diluted EPS of AU$0.95.Revenue from ordinary activities for the year ended Dec. 31, 2024, was AU$227.8 million, down from AU$240.1 million a year earlier. Analysts surveyed by Visible Alpha expected AU$194.8 million.Neuren anticipates earning royalties of AU$62 million to AU$67 million, assuming its global partner for trofinetide, Nasdaq-listed Acadia, meets its full-year net sales guidance of $380 million to $405 million for 2025, per the filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU"],"gpt_icon":0},{"id":"2514591053","title":"Neuren Pharmaceuticals Posts 2024 EPS of AU$1.0861, Revenue of AU$227.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514591053","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514591053?lang=en_us&edition=fundamental","pubTime":"2025-02-28 06:37","pubTimestamp":1740695852,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Posts 2024 EPS of AU$1.0861, Revenue of AU$227.8 Million","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":95,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[]}}